Previous Section Index Home Page

5 Jun 2007 : Column 428W—continued


Tickets: Touting

Mr. Don Foster: To ask the Secretary of State for the Home Department how many (a) prosecutions and (b) convictions for (i) online and (ii) offline offences there were of ticket touts under the Criminal Justice and Public Order Act 1994 in each year since it came into effect. [138878]

Mr. Coaker: The law on ticket touting in respect of football matches was amended to cover internet transactions within England and Wales in the Violent Crime Reduction Act 2006. Prior to that amendment, internet ticket touting was not a criminal offence. Detailed information on football-related arrests and convictions has been collated by the Football Banning Orders Authority since the football season 2001-02 when the existing banning order framework was introduced. The following table provides details of convictions in respect of ticket touting offences.

Convictions under section 166 of the Criminal Justice and Public Order Act 1994, England and Wales, 2001-06
Football Season Convictions

2001-02

28

2002-03

25

2003-04

25

2004-05

28

2005-06

24

Source: Football Banning Orders Authority.

5 Jun 2007 : Column 429W

Written Questions

James Duddridge: To ask the Secretary of State for the Home Department when he will write to the hon. Member for Rochford and Southend East with the information requested in Question 68481, on prisoner deportation, tabled on 2 May 2006. [127575]

Mr. Byrne [holding answer 15 March 2007] : I wrote to the hon. Member on 2 May 2007.

Health

Accident and Emergency Departments

Mr. Burrowes: To ask the Secretary of State for Health (1) what assessment she has made of the consistency of Sir George Alberti’s statement in the report to NHS London Review of Clinical Case for Change: Barnet, Enfield and Haringey Clinical Strategy, that nationally, it is apparent that one accident and emergency department can serve 400,000 to 500,000 population and two sites would be appropriate for the catchment population of 900,000 with the White Paper, Our Health, Our Care, Our Say; [140542]

(2) what assessment she has made of the consistency of Sir George Alberti’s report to NHS London Review of Clinical Case for Change: Barnet, Enfield and Haringey Clinical Strategy with the White Paper, Our Health, Our Care, Our Say. [140543]

Andy Burnham: None. This was a report from Sir George Alberti to NHS London.

Air Ambulance Services: Parliament Square

Stephen Pound: To ask the Secretary of State for Health what steps she is taking to ensure that the physical obstructions in Parliament square do not prevent an air ambulance landing at that location if required. [139934]

Gillian Merron: I have been asked to reply.

The London Air Ambulance (Virgin HEMS) has strict operating protocols regarding ad hoc landings in the congested area of London that take into consideration the size of the site, surrounding obstructions and the performance of the aircraft. A possible landing in Parliament square would be no different, in this regard, to landing at any other congested area site.

Arthritis: Drugs

Joan Walley: To ask the Secretary of State for Health (1) what her estimate is of the number of deaths there were in the UK directly resulting from the prescription of the rheumatoid arthritis drug methotrexate in each of the last three years; [135343]

(2) what her estimate is of the number of deaths there were in the UK directly resulting from the prescription of the rheumatoid arthritis drug leflunomide in each of the last three years; [135344]


5 Jun 2007 : Column 430W

(3) what her estimate is of the number of deaths there were in the UK directly resulting from the prescription of the rheumatoid arthritis drugs methotrexate and leflunomide in conjunction in each of the last three years. [135345]

Caroline Flint: Methotrexate is used in the treatment of a variety of conditions, such as rheumatoid arthritis and cancers (including leukaemias, non-Hodgkin’s lymphoma and head and neck cancer). Leflunomide (Arava) is used in the treatment of rheumatoid arthritis and psoriatic arthritis. Leflunomide is not authorised for use in conjunction with any other disease-modifying medicine, such as methotrexate.

Reports of suspected adverse drug reactions (ADRs) are collected by the Medicines and Healthcare products Regulatory Agency (MHRA) and the Commission for Human Medicines (CHM) through the spontaneous reporting scheme, the yellow card scheme.

For the three year period up to 30 April 2007, the MHRA/CHM had received a total of 19 spontaneous reports of suspected ADRs with a fatal outcome in association with methotrexate when used in the treatment of rheumatoid arthritis. In the majority of the 19 reports the cause of death was attributed to lung disorders (such as pulmonary fibrosis and pneumonitis) and infections (septicaemia/septic shock). There were seven reports with a fatal outcome that were reported in association with leflunomide therapy. The cause of death in the seven reports was attributed to liver failure (one), lung disorder (two), heart attack (one), chest infection (one) and toxic epidermal necrolysis (two). The MHRA has not received any ADR reports with a fatal outcome associated with the combined use of methotrexate and leflunomide.

It is important to note that the submission of a suspected ADR report does not necessarily mean that it was caused by the drug. Many factors have to be taken into account in assessing causal relationships including temporal association, the possible contribution of concomitant medications and the patient's underlying disease. Patients with rheumatoid arthritis are at increased risk of developing serious infections and lung disorders as part of the natural disease process even in the absence of drug treatment.

The product information for methotrexate and leflunomide which is provided to doctors and patients has extensive information regarding the risk of developing serious lung disorders and infections. The product information also mentions the need for patients to have a full blood count and liver function tests before starting treatment and at regular intervals thereafter to detect potential adverse effects on the blood and liver. As with all medicines, the MHRA and CHM will continue to closely monitor the safe use of methotrexate and leflunomide.

Breast Cancer: Screening

Norman Lamb: To ask the Secretary of State for Health how many breast screenings were undertaken by each primary care trust in each of the last five years, broken down by age group; how many invitations were sent out by each PCT for breast screening in each of the last five years; and what estimate her Department
5 Jun 2007 : Column 431W
has made of the attendance take-up rate of breast screenings for each PCT. [138415]

Ms Rosie Winterton: The data requested has been placed in the Library.

Cancer: Health Services

Mrs. Ellman: To ask the Secretary of State for Health what plans she has to establish a cancer centre in Liverpool; and if she will make a statement. [139278]

Ms Rosie Winterton: The board of Liverpool primary care trust decided on 22 May 2007 that breast cancer services for the city would be centralised at the Royal Liverpool University hospital. The Royal Liverpool and Broadgreen University hospitals NHS trust is now planning to build a dedicated ward for breast cancer care.

Childbirth

Angela Browning: To ask the Secretary of State for Health what representations she has received on compliance with the National Institute for Health and Clinical Excellence's recommendation on monitoring foetal heart beats in the first and second stages of labour in hospital maternity units; and if she will make a statement. [140578]

Mr. Ivan Lewis [holding answer 4 June 2007]: None. The national service framework for children, young people and maternity services states that maternity services should comply with the National Institute for Health and Clinical Excellence guidelines for the provision of high quality clinical care including the provision of ante-natal, intrapartum and post-partum and caesarean sections, as and when they are available and updated.

Chronic Fatigue Syndrome

Mr. Hancock: To ask the Secretary of State for Health what discussion her Department has had with the Medical Research Council on funding for biomedical research into myalgic encephalomyelitis/chronic fatigue syndrome. [138398]

Andrew Stunell: To ask the Secretary of State for Health what representations she has made to the Medical Research Council on funding into bio-medical research on myalgic encephalomyelitis; and if she will make a statement. [139025]

Mr. Amess: To ask the Secretary of State for Health whether her Department has held any discussions with the Medical Research Council on funding for biomedical research into myalgic encephalomyelitis/chronic fatigue syndrome. [139576]

Mr. Ivan Lewis: Following the publications of the report of his independent working group on chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) in 2002, the chief medical officer asked the Medical Research Council to develop a research strategy to advance biomedical and health services research in this area. The MRC responded in May 2003
5 Jun 2007 : Column 432W
with the publication of a “Research Strategy for CFS/ME” developed by an independent scientific research advisory group.

Sir David Cooksey’s report “A review of UK health research funding” recommended a single health research fund and the establishment of the Office for Strategic Coordination of Health Research to act as a central co-ordinating body for health research. The MRC and the Department’s National Institute for Health Research will in future be subject to these new oversight and funding arrangements.

Mr. Hancock: To ask the Secretary of State for Health what steps her Department has taken to ensure the continuance of specialist services for myalgic encephalomyelitis/chronic fatigue syndrome following the movement from primary care trust baseline budgets to the NHS bundle. [139755]

Mr. Ivan Lewis: From 2006-07, money’s previously held within central budgets for allocation to the national health service have now been included within a single budget (the NHS bundle) as a block sum for strategic health authorities to manage. To ensure that the desired outcomes are achieved, the 2007-08 bundle is supplemented by a service level agreement, which includes details of the services to be provided from the bundle, including services for myalgic encephalomyelitis/chronic fatigue syndrome, and the governance and accountability arrangements.

Chronically Sick: North East Region

Dr. Kumar: To ask the Secretary of State for Health what percentage of people in Middlesbrough South and East Cleveland have long-term illnesses. [139840]

Mr. Ivan Lewis: This information is not collected centrally.

Dental Services

Dr. Murrison: To ask the Secretary of State for Health how many (a) full and (b) partial dentures have been provided by NHS dentists in each quarter since 1997, broken down by strategic health authority. [138747]

Ms Rosie Winterton: The requested information for the period 1 January 1998 to 31 March 2006 has been placed in the Library.

The information requested is only available until 31 March 2006. The information was collected as part of the previous remuneration system in place until April 2006. Dentists no longer submit claims for individual items of service but report overall courses of treatment delivered.

Dr. Murrison: To ask the Secretary of State for Health (1) how many denture repairs were provided by the NHS in each quarter since 1997; and at what cost in each quarter; [138748]

(2) how many units of dental activity were expended on denture repairs in each quarter since 1 April 2006. [138749]


5 Jun 2007 : Column 433W

Ms Rosie Winterton: The requested information on numbers of denture repairs and their cost is provided in the following table for the period 1 January 1998 to 31 March 2006.

The information requested is only available until 31 March 2006. The information was collected as part of the previous remuneration system in place until April 2006. Dentists no longer submit claims for individual items of service but report overall courses of treatment delivered.

Information therefore cannot be provided on the number of denture repairs, their cost, or the units of dental activity used to provide such denture repairs since 1 April 2006.


5 Jun 2007 : Column 434W
Denture repair treatment and cost of treatment carried out by national health service dentists for each quarter in England from 1 January 1998 to 31 March 2006
Denture repairs treatments Cost (£) Denture relining or adjustments treatments Cost (£)

January-March 1998

118,273

1,407,021

28,206

800,548

April-June 1998

114,184

1,395,472

28,197

820,208

July-September 1998

109,531

1,362,453

27,956

824,892

October-December 1998

114,213

1,425,089

29,680

878,600

January-March 1999

111,093

1,393,633

26,120

778,177

April-June 1999

103,465

1,319,852

30,815

826,008

July-September 1999

102,963

1,365,690

37,704

910,963

October-December 1999

106,765

1,379,631

35,945

940,835

January-March 2000

102,044

1,315,794

24,613

750,986

April-June 2000

103,290

1,358,346

27,502

835,315

July-September 2000

98,704

1,317,454

27,316

836,364

October-December 2000

97,046

1,295,135

27,167

837,356

January-March 2001

95,411

1,271,837

23,486

725,943

April-June 2001

94,872

1,292,267

24,524

783,937

July-September 2001

91,511

1,268,707

24,763

811,515

October-December 2001

93,743

1,298,810

27,605

860,490

January-March 2002

89,115

1,235,349

24,297

739,403

April-June 2002

90,738

1,282,070

24,414

784,069

July-September 2002

87,843

1,262,638

22,143

760,304

October-December 2002

89,527

1,289,283

23,308

800,751

January-March 2003

84,718

1,221,262

19,856

680,961

April-June 2003

86,091

1,244,682

21,191

728,213

July-September 2003

82,828

1,223,015

21,251

741,809

October-December 2003

84,932

1,263,229

21,995

777,455

January-March 2004

81,427

1,212,089

18,747

658,133

April-June 2004

78,618

1,178,550

19,697

696,104

July-September 2004

73,520

1,124,692

18,674

668,735

October-December 2004

77,138

1,182,991

20,165

725,292

January-March 2005

74,521

1,141,723

17,524

627,877

April-June 2005

73,239

1,146,519

18,755

688,770

July-September 2005

68,042

1,076,791

18,069

671,954

October-December 2005

68,217

1,084,676

18,813

701,295

January-March 2006

64,756

1,026,163

16,695

621,349

Notes:
1. Claims are allocated to the quarter in which they were reported and processed and not necessarily when the work was carried out.
2. Data only includes treatments reported and processed up to 31 March 2006.
3. Denture repairs are described as following treatment codes in the Statement of Dental Remuneration: 2801, 2802, 2811, 2812, 5501, 5502, 5503, 5504, 5511, 5512
4. Dental Relining and Adjustment are described as following treatments codes in Statement of Dental Remuneration:
2851, 2852, 2853, 2854, 2855, 2856, 5531, 5532, 5541, 5543, 5551, 5552, 5553, 5554, 5555, 5556.
5. These have been counted as the number of treatments performed on a claim. (If the same treatment code appears twice on the claim it will be counted twice).
6. Treatment cost (£) is the cost of the treatments.
Source:
The Information Centre for health and social care Business Services Authority (BSA) Dental Practice Division.

Next Section Index Home Page